Delivering the future of immunotherapy: A state-of-the-art review of gene editing in immune cells with lipid nanoparticles
Abstract
use. Lipid nanoparticles (LNPs) have emerged as a clinically validated, scalable, and biocompatible alternative capable of delivering CRISPR cargo in the form of DNA, mRNA, or ribonucleoproteins. Recent innovations, including selective organ targeting, ligand conjugation, and sequence-level translational control are expanding their precision and versatility in immune cell engineering. Despite these advances, major challenges remain, including suboptimal endosomal escape, extrahepatic targeting, and immune trade-offs such as the PEG dilemma. By critically synthesizing current progress and limitations, this review highlights the central role of LNPs in enabling CRISPR-based immune engineering and outlines future directions for clinical translation
Fields of Study & Subjects
RNA Interference and Gene Delivery
CRISPR and Genetic Engineering
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Materials Today Bio
- Publisher
- Elsevier BV
- Volume
- 39
- Pages
- 103334–103334
- Publication date
- 8 June 2026
- Language
- EN